Ignite Creation Date:
2024-05-05 @ 10:07 PM
Last Modification Date:
2024-10-26 @ 10:14 AM
Study NCT ID:
NCT01037517
Status:
COMPLETED
Last Update Posted:
2013-10-31
First Post:
2009-12-18
Brief Title:
Trial of an Augmented Mobilization Strategy With Plerixafor Mozobil in a Population at Risk for Poor Stem Cell Mobilization
Sponsor:
CancerCare Manitoba
Organization:
CancerCare Manitoba
Study Overview
Official Title:
Open Label Phase II Trial of an Augmented Mobilization Strategy With Plerixafor Mozobil in a Population at Risk for Poor Stem Cell Mobilization
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem We are investigating the role of plerixafor administered in an at risk population to augment successful stem cell collection
OBJECTIVES
To determine if plerixafor when administered on the day prior to planned autologous collection on first mobilization attempt in those with a peripheral blood CD34 10X106L will
increase the number of patients successfully collected in one day
increase the number of patients successfully mobilized on first collection attempt
is cost neutral within a Canadian setting
OBJECTIVES
To determine if plerixafor when administered on the day prior to planned autologous collection on first mobilization attempt in those with a peripheral blood CD34 10X106L will
increase the number of patients successfully collected in one day
increase the number of patients successfully mobilized on first collection attempt
is cost neutral within a Canadian setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None